

<b>Report title</b>	Monthly Finance Performance Report Month 06 – September 2022
<b>Report from</b>	Jonathan Wilson, Chief Financial Officer
<b>Prepared by</b>	Justin Betts, Deputy Chief Financial Officer
<b>Link to strategic objectives</b>	Deliver financial sustainability as a Trust

<b>Executive summary</b>								
<b>Income and Expenditure</b>								
For September, the Trust is reporting:-								
<ul style="list-style-type: none"> <li>a £0.98m deficit year to date compared to a deficit plan of £2.51m, a £1.53m favourable variance.</li> </ul>								
<b>Financial Performance £m</b>	Annual Plan	In Month			Year to Date			
		Plan	Actual	Variance	Plan	Actual	Variance	%
Income	£287.5m	£26.0m	£26.4m	£0.4m	£139.9m	£136.1m	(£3.8m)	(3)%
Pay	(£155.3m)	(£14.3m)	(£14.1m)	£0.2m	(£77.4m)	(£76.0m)	£1.4m	2%
Non Pay	(£114.2m)	(£10.4m)	(£9.9m)	£0.5m	(£57.1m)	(£53.4m)	£3.8m	7%
Financing & Adjustments	(£16.4m)	(£1.3m)	(£1.5m)	(£0.2m)	(£7.9m)	(£7.7m)	£0.2m	3%
<b>CONTROL TOTAL</b>	<b>£1.6m</b>	<b>£0.1m</b>	<b>£0.9m</b>	<b>£0.9m</b>	<b>(£2.5m)</b>	<b>(£1.0m)</b>	<b>£1.5m</b>	
<ul style="list-style-type: none"> <li>Activity levels recorded in September compared to 2019/20 activity levels were 70% of A&amp;E activity, 102% Elective, 87% for Outpatients (excluding additive capacity or 96% inclusive), and 111% of Injection activity.</li> <li>Clinical income in month continues to be estimated based on draft guidance and subject to contracts being signed. National guidance in relation to the formal calculation of income linked to Elective Recovery Funding (ERF) remains in draft, and contracts have not been signed.</li> </ul>								
<b>Capital Expenditure</b>								
<ul style="list-style-type: none"> <li>Capital expenditure at 30th September totalled £5.1m, against an internal plan of £9.8m, £4.6m adverse to plan due to underspends on Oriol £1.9m, New Cavendish Street £1.5m and other delivery timeframe slippage of divisional schemes. <ul style="list-style-type: none"> <li>For business as usual schemes, £8.3m has been committed compared with available funding of £9.4m.</li> <li>TIF Funds of £8.0m have been approved and are progressing via a dedicated TIF programme board;</li> <li>Oriol pans of £52.7m now include confirmation that £14.9m will be received via the National Hospitals Programme rather than NCL ICB envelopes.</li> </ul> </li> </ul>								
<b>Quality implications</b>								
Patient safety has been considered in the allocation of budgets.								
<b>Financial implications</b>								
Delivery of the financial control total will result in the Trust being eligible for additional benefits that will support its future development.								
<b>Risk implications</b>								
Potential risks have been considered within the reported financial position and the financial risk register is discussed at the Audit Committee.								
<b>Action Required/Recommendation</b>								
The board is asked to consider and discuss the attached report.								
<b>For Assurance</b>		<b>For decision</b>		<b>For discussion</b>	✓	<b>To note</b>	✓	